Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Clinical Laboratory Techniques
/ standards
Diagnosis, Differential
Early Diagnosis
Female
Humans
Janus Kinase 2
/ antagonists & inhibitors
Male
Middle Aged
Molecular Targeted Therapy
Neoplasm Proteins
/ antagonists & inhibitors
Nitriles
Organ Size
Primary Myelofibrosis
/ diagnosis
Protein Kinase Inhibitors
/ therapeutic use
Pyrazoles
/ therapeutic use
Pyrimidines
Retrospective Studies
Spleen
/ pathology
Thrombocythemia, Essential
/ diagnosis
Treatment Outcome
World Health Organization
EARLY PMF
MYELOFIBROSIS
OVERT PMF
RUXOLITINIB
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
13
03
2019
revised:
02
04
2019
accepted:
11
04
2019
pubmed:
16
4
2019
medline:
20
11
2019
entrez:
16
4
2019
Statut:
ppublish
Résumé
The 2016 WHO criteria identified early primary myelofibrosis (PMF) as an individual entity with milder clinical features and better outcome compared with overt PMF. Here, we compared early and overt PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response, and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of hematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts. The application of 2016 WHO criteria is crucial to identify those PMF patients who deserve a stricter monitoring during treatment.
Substances chimiques
Antineoplastic Agents
0
Neoplasm Proteins
0
Nitriles
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
ruxolitinib
82S8X8XX8H
JAK2 protein, human
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
418-423Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Palandri F, Latagliata R, Polverelli N, et al. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia. 2015;29(6):1344-1349.
Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin Oncol. 2011;29(23):3179-3184.
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 2009;114(5):937-951.
Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
Barbui T, Tefferi A, Vannucchi AM. Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet. 2018.
Guglielmelli P, Pacilli A, Rotunno G, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129(24):3227-3236.
Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132.
Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International working group-myeloproliferative neoplasms research and treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395-1398.
Palandri F, Palumbo GA, Bonifacio M, et al. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leuk Res. 2018;74:86-88.
Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic international prognostic scoring system (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15):2857-2858.
Al-Ali HK, Stalbovskaya V, Gopalakrishna P, Perez-Ronco J, Foltz L. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. Leuk Lymphoma. 2016;57(10):2464-2467.
Palandri F, Palumbo GA, Bonifacio M, et al. Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis. Oncotarget. 2017;8(45):79073-79086.
Polverelli N, Breccia M, Benevolo G, et al. Risk factors for infections in myelofibrosis: Role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol. 2017;92(1):37-41.